{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:03:06Z","timestamp":1761163386863,"version":"build-2065373602"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2137,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p>Percy Medicine is a nonprescription gastrointestinal suspension containing bismuth subsalicylate as the active ingredient (1050 mg\/10\u2010ml dose). A 3\u2010month\u2010old infant with colic developed salicylate toxicity requiring hospitalization in the pediatric intensive care unit (PICU) as a result of continued administration of this medicine. Bismuth subsalicylate has an aspirin equivalency conversion factor of 0.479 (approximately half the strength of aspirin). For 3.5 weeks the infant's parents administered the medicine, which provided the equivalent of aspirin 57\u201384 mg\/kg\/day with no reported problems. However, on the day of admission the baby presented with central nervous system depression and respiratory distress. Assessment at a local emergency facility revealed metabolic acidosis; his serum salicylate concentration was 747 mg\/L. After acute management, the patient was transferred to our hospital, where he was treated with whole bowel irrigation and alkalinization therapy. Subsequently, the baby required 4 days of management in the PICU and 2 additional days of observation in a general nursing unit before he was discharged home without incident. The parents had chosen Percy Medicine based on the picture of a baby on the front of the package and because of its placement on the shelf next to a drug their family physician had recommended previously. Salicylate\u2010containing products are not routinely recommended for children aged 1 year or younger. The general public may assume that over\u2010the\u2010counter products are safe because they do not require a prescription. Health care professionals must be responsible for educating the public regarding risks associated with over\u2010the\u2010counter products and the need to read and follow label directions.<\/jats:p>","DOI":"10.1592\/phco.26.3.403","type":"journal-article","created":{"date-parts":[[2006,2,27]],"date-time":"2006-02-27T08:49:56Z","timestamp":1141030196000},"page":"403-409","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Salicylate Toxicity Associated with Administration of Percy Medicine in an Infant"],"prefix":"10.1002","volume":"26","author":[{"given":"Teresa V.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randal","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy M.","family":"Hagemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"McGoodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"Merrick Medicine.Percy Medicine. Available fromhttp:www.percymedicine.com. Accessed January 31 2005."},{"volume-title":"Poisindex system","year":"2005","author":"Anonymous","key":"e_1_2_1_3_2"},{"key":"e_1_2_1_4_2","first-page":"1135","volume-title":"Pediatric dosage handbook","author":"Taketomo C.K.","year":"2005"},{"key":"e_1_2_1_5_2","first-page":"85","volume-title":"Aspirin in modern therapy: a review","author":"Tainter M.L.","year":"1969"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"volume-title":"Vital statistics of the United States, volume 2: annual mortality data (public\u2010use files)","year":"1958","author":"National Center for Health Statistics","key":"e_1_2_1_7_2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.156.9.929"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2004.06.001"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/emj.19.3.206"},{"key":"e_1_2_1_11_2","first-page":"569","volume-title":"Goldfrank's toxicologic emergencies","author":"Flomenbaum N.E.","year":"1998"},{"key":"e_1_2_1_12_2","first-page":"742","volume-title":"Medical toxicology","author":"Yip L.","year":"2004"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1201\/9781439810873","volume-title":"Comprehensive review in toxicology for emergency clinicians","author":"Bryson P.D.","year":"1996"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0733-8627(20)30432-6","article-title":"Concepts and controversies in salicylate toxicity","volume":"12","author":"Yip L.","year":"1994","journal-title":"Emerg Med Clin North Am"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-200045006"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120037421"},{"issue":"2","key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1081\/CLT-51867","article-title":"Position paper: single\u2010dose activated charcoal [review]","volume":"43","author":"Chyka P.A.","year":"2005","journal-title":"Clin Toxicol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-200035932"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120028740"},{"key":"e_1_2_1_20_2","first-page":"346","volume-title":"Pharmaceutical dosage forms and drug delivery systems","author":"Ansel H.C.","year":"1999"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.3.403","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.3.403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:25:29Z","timestamp":1761067529000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.3.403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1592\/phco.26.3.403"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.3.403","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}